Human leukocyte antigen class II antigen presentation pathway (HLA-II pathway) (HLA-II pathway)

The Human leukocyte antigen (HLA) class II antigen presentation pathway is a fundamental immunological process responsible for presenting exogenous antigens to CD4+ helper T cells to initiate adaptive immune responses [2, 4]. This pathway involves the synthesis of HLA class II heterodimers (HLA-DR, HLA-DQ, and HLA-DP) in the endoplasmic reticulum, where they associate with the invariant chain (CD74) to prevent premature peptide binding and facilitate trafficking to endosomal compartments [8, 15]. Within these acidic compartments, antigens are proteolytically processed into peptides, and the invariant chain is degraded, leaving the CLIP fragment in the binding groove [11, 13]. The chaperone HLA-DM then facilitates the exchange of CLIP for high-affinity antigenic peptides, and the resulting complexes are transported to the cell surface for T cell recognition [7, 12]. Dysregulation of this pathway is a key mechanism in various diseases: tumors often downregulate HLA class II expression to evade immune detection, while the inappropriate presentation of self-antigens is central to the development of autoimmune disorders such as type 1 diabetes and multiple sclerosis [4, 6, 10]. Therapeutic strategies targeting this pathway include MHC class II agonists like eftilagimod alfa to enhance anti-tumor immunity, and various modulators or blocking antibodies designed to suppress or redirect immune responses in autoimmunity and transplantation [5, 14]. Additionally, drugs like hydroxychloroquine modulate this pathway by altering the lysosomal pH, thereby affecting antigen processing and presentation [5]. Overall, the HLA class II pathway serves as a critical bridge between innate and adaptive immunity and is a versatile target for both immune stimulation and suppression.

Other names

MHC class II antigen presentation pathwayHLA class II antigen-processing machineryExogenous antigen presentation pathwayMHCII pathway

The pathway is modulated through several distinct mechanisms: MHC class II agonism (e.g., eftilagimod alfa) to activate antigen-presenting cells and boost T cell responses; blockade of HLA-DR or HLA-DQ (e.g., IMMU-114, DONQ52) to prevent the presentation of specific antigens; inhibition of the invariant chain (CD74) to disrupt trafficking and signaling; and inhibition of lysosomal acidification (e.g., hydroxychloroquine) to impair antigen processing.